CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Aspirin

阿司匹林 杂质对照品Aspirin Impurities

EP34 个杂质条目34 impurity entries

本页汇总 阿司匹林 的 34 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 34 impurity reference standards of Aspirin with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 阿司匹林(Aspirin)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 分析方法Analytical MethodsAn effective and stability-indicating method development and optimization utilizing the Box-Behnken design for the simultaneous determination of acetaminophen, caffeine, and aspirin in tablet formulation
    Biomedical chromatography : BMC · 2023 · Yenda P et al.  ·  PMID 36692333  ·  DOI
  2. 分析方法Analytical MethodsSpectrophotometric Determination of Aspirin and Omeprazole in the Presence of Salicylic Acid as a Degradation Product: A Comparative Evaluation of Different Univariate/Multivariate Post Processing Algorithms
    Journal of AOAC International · 2022 · Elmasry MS et al.  ·  PMID 34387326  ·  DOI
  3. 分析方法Analytical MethodsStability-indicating RP-HPLC-DAD method for aspirin and vonoprazan using analytical quality by design and comprehensive greenness assessment
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2026 · Ajmeera M et al.  ·  PMID 42309002  ·  DOI
  4. 分析方法Analytical MethodsValidated stability-indicating reversed-phase-HPLC method for simultaneous determination of orphenadrine citrate, caffeine and aspirin
    Chemical & pharmaceutical bulletin · 2012 · Darwish K et al.  ·  PMID 23124566  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisStereocontrolled total synthesis of neuroprotectin D1 / protectin D1 and its aspirin-triggered stereoisomer
    Tetrahedron letters · 2012 · Petasis NA et al.  ·  PMID 22690022  ·  DOI

阿司匹林 —— 原料药与杂质对照品Aspirin — drug substance & impurities

共 34 个条目(含原料药本体)34 items incl. the drug substance
Acetylsalicylic Acid EP Impurity A (Salicylic Acid EP Impurity A, Salicylic Acid USP Related Compound A) structure
EPA
乙酰水杨酸杂质1(乙酰水杨酸EP杂质A)Acetylsalicylic Acid EP Impurity A (Salicylic Acid EP Impurity A, Salicylic Acid USP Related Compound A)
Acetylsalicylic Acid EP Impurity A (Salicylic Acid EP Impurity A, Salicylic Acid USP Related Compound A)
CAS No.99-96-7
Chemical FormulaC7H6O3
Purity>95%询价On request
10mg25mg50mg100mg
Acetylsalicylic Acid EP Impurity B (Salicylic Acid USP Related Compound B) structure
EPB
乙酰水杨酸杂质2(乙酰水杨酸EP杂质B)Acetylsalicylic Acid EP Impurity B (Salicylic Acid USP Related Compound B)
Acetylsalicylic Acid EP Impurity B (Salicylic Acid USP Related Compound B)
CAS No.636-46-4
Chemical FormulaC8H6O5
Purity>95%询价On request
10mg25mg50mg100mg
Acetylsalicylic Acid EP Impurity D (Carbasalate Calcium EP Impurity B, Acetylsalicylsalicylic Acid) structure
EPD
乙酰水杨酸杂质4(乙酰水杨酸EP杂质D)Acetylsalicylic Acid EP Impurity D (Carbasalate Calcium EP Impurity B, Acetylsalicylsalicylic Acid)
Acetylsalicylic Acid EP Impurity D (Carbasalate Calcium EP Impurity B, Acetylsalicylsalicylic Acid)
CAS No.530-75-6
Chemical FormulaC16H12O6
Purity>95%询价On request
10mg25mg50mg100mg
Acetylsalicylic Acid EP Impurity E (Carbasalate Calcium EP Impurity D, Salsalate) structure
EPE
乙酰水杨酸杂质5 (乙酰水杨酸EP杂质E)Acetylsalicylic Acid EP Impurity E (Carbasalate Calcium EP Impurity D, Salsalate)
Acetylsalicylic Acid EP Impurity E (Carbasalate Calcium EP Impurity D, Salsalate)
CAS No.552-94-3
Chemical FormulaC14H10O5
Purity>95%询价On request
10mg25mg50mg100mg
Acetylsalicylic Acid EP Impurity F (Carbasalate Calcium EP Impurity A) structure
EPF
乙酰水杨酸杂质6(乙酰水杨酸EP杂质F)Acetylsalicylic Acid EP Impurity F (Carbasalate Calcium EP Impurity A)
Acetylsalicylic Acid EP Impurity F (Carbasalate Calcium EP Impurity A)
CAS No.1466-82-6
Chemical FormulaC18H14O7
Purity>95%询价On request
10mg25mg50mg100mg
Acetylsalicylic Acid EP Impurity A-13C6 (Salicylic Acid EP Impurity A-13C6, Salicylic Acid USP Related Compound A-13C6) structure
EPA-13C6
乙酰水杨酸杂质1-13C(乙酰水杨酸EP杂质A)Acetylsalicylic Acid EP Impurity A-13C6 (Salicylic Acid EP Impurity A-13C6, Salicylic Acid USP Related Compound A-13C6)
Acetylsalicylic Acid EP Impurity A-13C6 (Salicylic Acid EP Impurity A-13C6, Salicylic Acid USP Related Compound A-13C6)
CAS No.287399-29-5
Chemical FormulaC13C6H6O3
Purity>95%询价On request
10mg25mg50mg100mg
5-(N-β-D-Glucopyranosylamino) Salicylic Acid structure
—
美沙拉秦杂质305-(N-β-D-Glucopyranosylamino) Salicylic Acid
5-(N-β-D-Glucopyranosylamino) Salicylic Acid
CAS No.123135-21-7
Chemical FormulaC13H17NO8
Purity>95%询价On request
10mg25mg50mg100mg
5-Acetylsalicylic Acid structure
—
乙酰水杨酸杂质205-Acetylsalicylic Acid
5-Acetylsalicylic Acid
CAS No.13110-96-8
Chemical FormulaC9H8O4
Purity>95%询价On request
10mg25mg50mg100mg
Acetylsalicylic Acid Acyl-D-Glucuronide (Aspirin Acyl-D-Glucuronide) structure
—
乙酰水杨酸杂质18Acetylsalicylic Acid Acyl-D-Glucuronide (Aspirin Acyl-D-Glucuronide)
Acetylsalicylic Acid Acyl-D-Glucuronide (Aspirin Acyl-D-Glucuronide)
CAS No.24719-72-0
Chemical FormulaC15H16O10
Purity>95%询价On request
10mg25mg50mg100mg
Gentisuric Acid structure
—
Gentisuric Acid
CAS No.25351-24-0
Chemical Formula—
Purity>95%询价On request
10mg25mg50mg100mg
Salicylglycine structure
—
Salicylglycine
CAS No.487-54-7
Chemical Formula—
Purity>95%询价On request
10mg25mg50mg100mg
Acetylsalicylic Acid (Aspirin) structure
—
乙酰水杨酸Acetylsalicylic Acid (Aspirin)
Acetylsalicylic Acid (Aspirin)
CAS No.50-78-2
Chemical FormulaC9H8O4
Purity>95%询价On request
10mg25mg50mg100mg
3-Acetyl-2-Hydroxybenzoic Acid structure
—
3-Acetyl-2-Hydroxybenzoic Acid
CAS No.67127-78-0
Chemical Formula—
Purity>95%询价On request
10mg25mg50mg100mg
Salicylic Acid Phenolic beta-D-Glucuronide structure
—
乙酰水杨酸杂质19Salicylic Acid Phenolic beta-D-Glucuronide
Salicylic Acid Phenolic beta-D-Glucuronide
CAS No.7695-70-7
Chemical FormulaC13H14O9
Purity>95%询价On request
10mg25mg50mg100mg
Acetylsalicylsalicylsalicylic Acid structure
—
乙酰水杨酸杂质13Acetylsalicylsalicylsalicylic Acid
Acetylsalicylsalicylsalicylic Acid
CAS No.85531-16-4
Chemical FormulaC23H16O8
Purity>95%询价On request
10mg25mg50mg100mg
Acetylsalicylic Acid-d3 (Aspirin-d3) structure
—
乙酰水杨酸-d3Acetylsalicylic Acid-d3 (Aspirin-d3)
Acetylsalicylic Acid-d3 (Aspirin-d3)
CAS No.921943-73-9
Chemical FormulaC9H5D3O4
Purity>95%询价On request
Acetylsalicylic Acid-d4 (Aspirin-d4) structure
—
乙酰水杨酸-d4Acetylsalicylic Acid-d4 (Aspirin-d4)
Acetylsalicylic Acid-d4 (Aspirin-d4)
CAS No.97781-16-3
Chemical FormulaC9H4D4O4
Purity>95%询价On request
Acetylsalicylic Acid Impurity 1 structure
1
Acetylsalicylic Acid Impurity 1
CAS No.—
Chemical FormulaC16H12O6
Purity>95%询价On request
10mg25mg50mg100mg
Acetylsalicylic Acid Impurity 2 structure
2
乙酰水杨酸杂质40Acetylsalicylic Acid Impurity 2
Acetylsalicylic Acid Impurity 2
CAS No.318515-20-7
Chemical FormulaC12H10N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Acetylsalicylic Acid Impurity 3 structure
3
乙酰水杨酸杂质10Acetylsalicylic Acid Impurity 3
Acetylsalicylic Acid Impurity 3
CAS No.15540-79-1
Chemical FormulaC8H7NO5
Purity>95%询价On request
10mg25mg50mg100mg
Acetylsalicylic Acid Impurity 5 structure
5
乙酰水杨酸杂质11Acetylsalicylic Acid Impurity 5
Acetylsalicylic Acid Impurity 5
CAS No.18698-59-4
Chemical FormulaC11H10O5
Purity>95%询价On request
10mg25mg50mg100mg
Acetylsalicylic Acid Impurity 6 Sodium Salt (Sodium Methyl Parahydroxybenzoate) structure
6
羟苯甲酯钠Acetylsalicylic Acid Impurity 6 Sodium Salt (Sodium Methyl Parahydroxybenzoate)
Acetylsalicylic Acid Impurity 6 Sodium Salt (Sodium Methyl Parahydroxybenzoate)
CAS No.5026-62-0
Chemical FormulaC8H7O3-·Na+
Purity>95%询价On request
10mg25mg50mg100mg
Acetylsalicylic Acid Impurity 7 structure
7
乙酰水杨酸杂质7Acetylsalicylic Acid Impurity 7
Acetylsalicylic Acid Impurity 7
CAS No.21725-69-9
Chemical FormulaC13H18N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Acetylsalicylic Acid Impurity 8 structure
8
乙酰水杨酸杂质8Acetylsalicylic Acid Impurity 8
Acetylsalicylic Acid Impurity 8
CAS No.89-86-1
Chemical FormulaC15H20N2O5
Purity>95%询价On request
10mg25mg50mg100mg
Acetylsalicylic Acid Impurity 9 structure
9
乙酰水杨酸杂质9Acetylsalicylic Acid Impurity 9
Acetylsalicylic Acid Impurity 9
CAS No.17540-51-1
Chemical FormulaC13H18N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Acetylsalicylic Acid Impurity 10 structure
10
Acetylsalicylic Acid Impurity 10
CAS No.—
Chemical FormulaC15H20N2O5
Purity>95%询价On request
10mg25mg50mg100mg
Acetylsalicylic Acid Impurity 11 structure
11
Acetylsalicylic Acid Impurity 11
CAS No.—
Chemical FormulaC13H18N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Acetylsalicylic Acid Impurity 12 structure
12
乙酰水杨酸杂质12Acetylsalicylic Acid Impurity 12
Acetylsalicylic Acid Impurity 12
CAS No.2513-33-9
Chemical FormulaC15H20N2O5
Purity>95%询价On request
10mg25mg50mg100mg
Acetylsalicylic Acid Impurity 13 HCl structure
13
Acetylsalicylic Acid Impurity 13 HCl
CAS No.—
Chemical FormulaC15H20N2O5.HCl
Purity>95%询价On request
10mg25mg50mg100mg
Acetylsalicylic Acid Impurity 14 structure
14
乙酰水杨酸杂质14Acetylsalicylic Acid Impurity 14
Acetylsalicylic Acid Impurity 14
CAS No.606-45-1
Chemical FormulaC10H10O5
Purity>95%询价On request
10mg25mg50mg100mg
Acetylsalicylic Acid Impurity 15 structure
15
乙酰水杨酸杂质15Acetylsalicylic Acid Impurity 15
Acetylsalicylic Acid Impurity 15
CAS No.619-66-9
Chemical FormulaC13H18N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Acetylsalicylic Acid Impurity 16 structure
16
乙酰水杨酸杂质16Acetylsalicylic Acid Impurity 16
Acetylsalicylic Acid Impurity 16
CAS No.23362-56-3
Chemical FormulaC15H20N2O5
Purity>95%询价On request
10mg25mg50mg100mg
Acetylsalicylic Acid Impurity 17 structure
17
乙酰水杨酸杂质17Acetylsalicylic Acid Impurity 17
Acetylsalicylic Acid Impurity 17
CAS No.408336-10-7
Chemical FormulaC8H5BrO3
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

阿司匹林 —— 研究文献与合成路线Aspirin — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 阿司匹林 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Aspirin. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Stability Indicating Assay Method and LC-MS Characterization of Forced Degradation Products of Pantoprazole and Aspirin
    Patel TS, Chaudhary AB · Journal of chromatographic science · 2025 · 被引 1cited 1
  2. Stability Indicating Liquid Chromatographic Method for Simultaneous Determination of Aspirin and Omeprazole
    Patel VB, Patel AD, Shah DA · Current drug discovery technologies · 2018 · 被引 5cited 5
  3. Comprehensive analysis of Aspirin and Apixaban: thedevelopment, validation, and forced degradation studies of bulk drugs and in-house capsule formulations using the RP-HPLC method
    Patel T, Patel M, Shah U, et al. · American journal of translational research · 2024 · 被引 2cited 2
  4. Aspirin inhibits proteasomal degradation and promotes α-synuclein aggregate clearance through K63 ubiquitination
    Gao J, Liu Y, Si C, et al. · Nature communications · 2025 · 被引 22cited 22
  5. Modulating Mechanical and Shape-Memory Properties while Mitigating Degradation-Induced Inflammation of Polylactides by Pendant Aspirin Incorporation
    Xu X, Zhang J, Filion TM, et al. · ACS applied materials & interfaces · 2021 · 被引 15cited 15
  6. Green analysis of newly approved binary omeprazole/aspirin mixture in presence of aspirin impurity using ultra-high-performance liquid chromatography and thin-layer chromatography methods
    Abdelaleem EA, Abou El Ella DA, Mahmoud AM, et al. · Biomedical chromatography : BMC · 2021 · 被引 6cited 6

合成与制备工艺专利Synthesis & process patents

  1. TECHNOLOGICAL PROCESS TO INCREASE CONVERSION OF ASPIRIN
    ANITA KOVAC KRALJ · 公开号 SI23180SI23180 · 2011
  2. Preparation method of improved di-lysine-aspirin
    WENJIE CHEN, LIXIN JIANG, HUI ZHAO, JIN ZHANG, et al. · 公开号 CN101633624CN101633624 · 2010
  3. BIOMARKER FOR DIAGNOSIS OF ASPIRIN HYPERSENSITIVITY, METHOD FOR MANUFACTURING THE SAME, AND METHOD FOR DIAGNOSIS OF ASPIRIN HYPERSENSITIVITY USING THE SAME
    PARK CHOON SIK, SHIN HYOUNG DOO · 公开号 KR20100012986KR20100012986 · 2010
  4. BIOMARKER FOR DIAGNOSIS OF ASPIRIN HYPERSENSITIVITY, METHOD FOR MANUFACTURING THE SAME, AND METHOD FOR DIAGNOSIS OF ASPIRIN HYPERSENSITIVITY USING THE SAME
    PARK CHOON-SIK, SHIN HYOUNG DOO · 公开号 WO2010013855WO2010013855 · 2010
  5. HIGH SHEAR PROCESS FOR ASPIRIN PRODUCTION
    HASSAN ABBAS, BAGHERZADEH EBRAHIM, ANTHONY RAYFORD G, BORSINGER GREGORY, et al. · 公开号 EP2152378EP2152378 · 2010

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

阿司匹林 杂质谱研究要点Aspirin — impurity profiling notes

下面这些是拿到 阿司匹林 的 34 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 34 impurity entries for Aspirin, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances